Latest News on NKTX

Financial News Based On Company


Advertisement
Advertisement

Nkarta, Inc. Stock 12‑Month Price Target Raised to $10.8, Implies 839% Upside

https://www.tradingview.com/news/tradingview:720d10e91aadc:0-nkarta-inc-stock-12-month-price-target-raised-to-10-8-implies-839-upside/
Five analysts have raised their average 12-month price target for Nkarta, Inc. (NKTX) stock from $10.5 to $10.8, with individual forecasts ranging from $9 to $12 per share. This new target implies an approximate 839% potential upside based on the November 18 closing price. The consensus rating among six covering analysts remains a "Buy."

Nkarta, Inc. (NKTX) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/NKTX/
This article provides a detailed financial overview of Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company focusing on natural killer cell therapies for cancer and autoimmune diseases. It includes current stock price, historical data, key financial metrics, analyst ratings, and a company profile outlining its lead product candidate NKX019 and collaboration with CRISPR Therapeutics AG.

Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026

https://www.globenewswire.com/news-release/2026/11/11/3400583/0/en/nkarta-presents-initial-safety-data-for-nkx019-in-40-patients-across-five-autoimmune-diseases-at-acr-convergence-2026.html
Nkarta, Inc. announced integrated safety results from 40 patients treated with NKX019, an allogeneic CAR NK cell therapy, across five autoimmune diseases in its Ntrust clinical trial program. The findings, presented at ACR Convergence 2026, show no cases of cytokine release syndrome, ICANS, IEC-HS, or GvHD, with grade 3 or higher adverse events being primarily hematologic and attributed to lymphodepletion. This suggests CAR NK cells could offer a differentiated approach to autoimmune cell therapy with a manageable safety profile compared to CAR T cells.

Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications

https://www.benzinga.com/markets/biotech/26/11/63146563/nkarta-announces-clean-safety-profile-for-cell-therapy-across-five-autoimmune-indications
Nkarta Inc. announced encouraging initial safety results for its experimental NKX019 cell therapy in 40 patients across five autoimmune diseases, with findings presented at the American College of Rheumatology’s ACR Convergence 2026 conference. The off-the-shelf therapy demonstrated strong clinical tolerability, reporting zero deaths and no severe immune toxicities. Participants, heavily pretreated, experienced manageable adverse events mostly attributed to preconditioning chemotherapy, and no patients discontinued treatment due to adverse events.

Nkarta reports no CRS or GvHD in 40-patient NKX019 safety data

https://www.streetinsider.com/Corporate+News/Nkarta+reports+no+CRS+or+GvHD+in+40-patient+NKX019+safety+data/27326232.html
Nkarta, Inc. presented positive integrated safety data for its NKX019 CAR NK cell therapy candidate, showing no cases of cytokine release syndrome (CRS), GvHD, or other severe immune-related adverse events across 40 patients with five autoimmune diseases. The data reinforces the potential for CAR NK cells as a differentiated approach to autoimmune cell therapy, with hematologic adverse events primarily attributed to lymphodepletion. CEO Paul J. Hastings highlighted the therapy's unique manufacturing process, which does not require patient leukapheresis.
Advertisement

Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026

https://investingnews.com/nkarta-presents-initial-safety-data-for-nkx019-in-40-patients-across-five-autoimmune-diseases-at-acr-convergence-2026/
Nkarta, Inc. announced positive initial safety data for NKX019, an allogeneic CAR NK cell therapy, in 40 patients across five autoimmune diseases. The Ntrust clinical program showed no cases of cytokine release syndrome, ICANS, IEC-HS, or GvHD, with grade 3 or higher adverse events primarily hematologic and attributed to lymphodepletion. This suggests CAR NK cells could offer a differentiated, safer approach to autoimmune cell therapy compared to CAR T cells, potentially allowing outpatient administration.

None of 40 patients died or stopped treatment due to side effects in Nkarta’s study.

https://www.stocktitan.net/news/NKTX/nkarta-presents-initial-safety-data-for-nkx019-in-40-patients-across-91tq0pw9evqf.html
Nkarta (Nasdaq: NKTX) presented initial safety results for its NKX019 cell therapy in 40 patients across five autoimmune diseases, showing no deaths or treatment discontinuations due to adverse events. The analysis reported no cytokine release syndrome or other severe immune-related toxicities. While 35% of patients experienced grade 3 or higher adverse events, these were predominantly blood-related and attributed to lymphodepleting preconditioning, generally resolving within one to two months.

NKTX: Nkarta Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

https://quantisnow.com/insight/nkarta-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6780681
Nkarta Inc. has filed an SEC Form 8-K disclosing initial Ntrust-2 data for its CAR NK therapy NKX019 in myositis and systemic sclerosis. The data showed promising clinical responses at the 4 billion cell dose without immune effector cell toxicities. The company reported $216 million in cash, with an expected runway into 2029, and plans further FDA discussions before settling on a registrational dose.

Form 8K Nkarta Inc For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-nkartainc-for-9-november-93CH-5691165
This article announces that Nkarta Inc. filed a Form 8K on November 9, 2026. The 8K filing is a standard SEC disclosure for significant corporate events. No specific details about the content of the Form 8K are provided within the article itself.

NKTX: Nkarta Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

https://www.quantisnow.com/insight/nkarta-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6780681
Nkarta Inc. has filed an SEC Form 8-K, disclosing initial Ntrust-2 clinical data for its CAR NK therapy, NKX019, in myositis and systemic sclerosis. The data showed promising clinical responses at the 4 billion cell dose without significant toxicities, and the company reported $216 million in cash, expecting a runway into 2029. However, the response figures are based on small patient groups, and a registrational dose has yet to be finalized.
Advertisement

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

https://investingnews.com/nkarta-announces-initial-clinical-data-for-nkx019-in-myositis-and-systemic-sclerosis-at-acr-convergence/
Nkarta (Nasdaq: NKTX) reported positive initial clinical data for its NKX019 CAR NK cell therapy in patients with myositis and systemic sclerosis from its Ntrust clinical trial program. The data, presented at ACR Convergence 2026, showed significant improvements in disease activity and a favorable safety profile across 40 patients. This encourages Nkarta to pursue potential registrational pathways, with plans to evaluate compressed dosing schedules and higher cell doses.

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

https://www.globenewswire.com/news-release/2026/11/09/3398226/0/en/nkarta-announces-initial-clinical-data-for-nkx019-in-myositis-and-systemic-sclerosis-at-acr-convergence.html
Nkarta announced positive initial clinical data for its NKX019 CAR NK cell therapy in treating myositis and systemic sclerosis, presented at ACR Convergence 2026. The Ntrust clinical trial showed high response rates in patients treated with 4 billion cells per dose, with favorable safety and tolerability profiles and no significant immune effector cell-associated toxicities. The company plans future interactions with the FDA to discuss potential registrational pathways for both indications.

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

https://finance.yahoo.com/healthcare/articles/nkarta-host-webcast-discuss-initial-210100493.html
Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, to discuss initial clinical data for its NKX019 program in myositis and systemic sclerosis at the ACR Convergence 2026. The Ntrust clinical trials (Ntrust-1 and Ntrust-2) are evaluating the safety and potential of NKX019, an allogeneic, off-the-shelf CAR-NK cell therapy, to achieve durable remission in patients with various autoimmune diseases by eliminating pathogenic B cells. NKX019 is engineered with a CD19-directed CAR and a membrane-bound form of interleukin-15 for enhanced targeting, persistence, and activity.

Nkarta to webcast initial clinical data for NKX019 in autoimmune diseases at ACR 2026

https://pluang.com/en/news-feed/nkarta-webcast-data-klinis-awal-nkx019-penyakit-autoimun-acr-2026
Nkarta, Inc. will host a webcast on November 9, 2026, to reveal initial clinical data for its NKX019 therapy, which targets autoimmune diseases like myositis and systemic sclerosis. This "off-the-shelf" engineered natural killer cell therapy is being evaluated in the Ntrust clinical trials for its ability to reset the immune system and potentially offer durable remission. The webcast will provide insights for investors monitoring the health sector, with details available on Nkarta's official website.

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

https://www.globenewswire.com/news-release/2026/11/06/3397882/0/en/nkarta-to-host-webcast-to-discuss-initial-clinical-data-for-nkx019-in-autoimmune-diseases-at-acr-convergence-2026.html
Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data for its NKX019 program in myositis and systemic sclerosis. This data will be presented at the American College of Rheumatology (ACR) Convergence 2026. The Ntrust clinical trials are evaluating NKX019, an allogeneic CAR-NK cell therapy, for safety and its potential to achieve durable remission in various autoimmune diseases by eliminating pathogenic B cells.
Advertisement

Initial trial data on an immune-cell treatment for autoimmune diseases will be discussed Monday.

https://www.stocktitan.net/news/NKTX/nkarta-to-host-webcast-to-discuss-initial-clinical-data-for-nkx019-90rktkyy5kg0.html
Nkarta (NKTX) is hosting a webcast on November 9, 2026, to discuss initial clinical data for its NKX019 program, which evaluates an engineered natural killer (NK) cell therapy for autoimmune diseases. The webcast will review Ntrust program data in myositis and systemic sclerosis, presented at the American College of Rheumatology Convergence 2026. This therapy aims to achieve durable remission by eliminating pathogenic B cells through lymphodepletion and CD19-targeted CAR-NK cell therapy.

Nkarta Announces November 9, 2026 Webcast to Present Initial NKX019 Clinical Data

https://kalkinemedia.com/us/news/announcements/nkarta-announces-november-9-2026-webcast-to-present-initial-nkx019-clinical-data
Nkarta, Inc. (NASDAQ:NKTX) will host a webcast on November 9, 2026, to present initial clinical data from its Ntrust program concerning NKX019, an experimental treatment for myositis and systemic sclerosis. This data was initially disclosed in a Form 8-K filing on November 6, 2026, and will also be showcased at the American College of Rheumatology (ACR) Convergence 2026. The webcast will provide further details on NKX019's early clinical findings.

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

https://investingnews.com/nkarta-reports-third-quarter-2026-financial-results-and-provides-business-update/
Nkarta, Inc. (Nasdaq: NKTX) reported its third-quarter 2026 financial results, highlighting a cash balance of $216.0 million, expected to fund operations into 2029. The company is advancing its NKX019 clinical program for autoimmune diseases like idiopathic inflammatory myopathy and systemic sclerosis, with initial clinical data scheduled for presentation at ACR Convergence 2026. Nkarta emphasized the potential for broader patient access through outpatient dosing of its off-the-shelf CAR-NK cell therapies.

Nkarta reports Q3 2026 results, advancing NKX019 trials with $216M cash to fund operations into 2029

https://pluang.com/en/news-feed/nkarta-laporkan-hasil-keuangan-q3-2026-dan-pembaruan-bisnis
Nkarta, Inc. announced its Q3 2026 financial results, highlighting significant progress in its NKX019 clinical trials for autoimmune diseases like myositis and systemic sclerosis. The company is set to present initial clinical data at ACR Convergence 2026, focusing on the safety and accessibility of its CAR-NK cell therapy. With $216 million in cash and investments, Nkarta expects to fund operations into 2029, as it works to expand outpatient dosing and patient access.

Form 8K Nkarta Inc For: 5 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-nkartainc-for-5-november-93CH-4936372
This article from Investing.com announces that Nkarta Inc. filed a Form 8K on November 5. The brief report highlights the filing for the company, and notes a -9.25% change in its stock symbol NKTX. The content is primarily a placeholder for the SEC filing announcement.
Advertisement

Nkarta, Inc. (NKTX) Misses Q3 EPS by 5c

https://www.streetinsider.com/Earnings/Nkarta%2C+Inc.+%28NKTX%29+Misses+Q3+EPS+by+5c/27301984.html
Nkarta, Inc. (NKTX) reported its Q3 EPS, which came in at ($0.45), missing the analyst estimate of ($0.40) by $0.05. The article highlights the company's financial performance for the quarter, indicating a miss on earnings expectations.

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/05/3397171/0/en/nkarta-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Nkarta, Inc. reported its third-quarter 2026 financial results, highlighting a cash balance of $216.0 million, projected to fund operations into 2029. The company also announced that initial clinical data for its NKX019 program in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) will be presented at ACR Convergence 2026. Nkarta is advancing its off-the-shelf CAR-NK cell therapies for autoimmune diseases, emphasizing outpatient dosing and broader patient access.

Nkarta, Inc. (NKTX) Seasonal returns chart

https://au.finance.yahoo.com/quote/NKTX/seasonality/
The article displays a seasonal returns chart for Nkarta, Inc. (NKTX), showing the average monthly price return from 2020 to 2026. It provides current stock information, including the real-time NasdaqGS price of 1.5450 USD, a decrease of 0.0150 (-0.96%). The chart helps visualize historical seasonality for the stock.

Nkarta, Inc. (NKTX) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/NKTX/seasonality/
This Yahoo Finance page provides a seasonal returns chart for Nkarta, Inc. (NKTX), displaying the average monthly price return from 2020 to 2026. The page also shows current stock performance, including a closing price of $1.56 and an after-hours price of $1.60 on October 30.

Nkarta, Inc. Estimates – NASDAQ:NKTX

https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-estimates/
This article provides an overview of Nkarta, Inc. (NASDAQ: NKTX) financial data and analyst estimates, available on TradingView. It allows users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.
Advertisement

Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11

https://www.moomoo.com/news/post/1000602876/needham-maintains-nkarta-nktxus-with-buy-rating-maintains-target-price
Needham has reiterated its Buy rating on Nkarta (NKTX.US) and maintained its target price at $11. This indicates continued confidence from the analyst firm in the company's prospects.

Nkarta, Inc. (NASDAQ:NKTX) Stock Has Average Price Target of $11.20 According to Brokerages

https://www.marketbeat.com/instant-alerts/consensus-nkarta-inc-nasdaq-nktx-stock-has-average-price-target-of-1120-according-to-brokerages-2026-09-28/
Nkarta, Inc. (NASDAQ:NKTX) has an average 12-month price target of $11.20 from brokerages, with a consensus "Moderate Buy" rating. Seven analysts cover the stock, with five "buy" ratings, one "strong buy," and one "sell." The clinical-stage biotech company, developing engineered natural killer cell therapies, opened at $2.75, with institutional investors owning 80.54% of its stock.

Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $10

https://www.moomoo.com/news/post/1000301146/stifel-maintains-nkarta-nktxus-with-buy-rating-maintains-target-price
Stifel has reiterated its Buy rating for Nkarta (NKTX.US) and maintained a target price of $10. This indicates a continued positive outlook from the firm regarding Nkarta's stock performance.

Stifel reiterates Buy rating on Nkarta stock, cites trial progress By Investing.com

https://ca.investing.com/news/stock-market-news/stifel-reiterates-buy-rating-on-nkarta-stock-cites-trial-progress-93CH-4855911
Stifel reiterated a Buy rating and $10.00 price target for Nkarta Inc. (NASDAQ:NKTX) shares, following discussions with company executives about protocol amendments in the Ntrust-1/2 trials aimed at improving patient convenience and enrollment. Nkarta plans to present preliminary data from these trials at ACR Convergence in November, focusing on efficacy and safety in myositis and scleroderma patients. The company is also working on enhancing NKX019's efficacy, with more comprehensive updates expected in fiscal year 2027 to assess its competitiveness in autoimmune disease treatment.

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

https://finance.yahoo.com/healthcare/articles/nkarta-targets-acr-2026-data-190204416.html
Nkarta (NASDAQ:NKTX) plans to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November. The company is advancing outpatient CAR NK trials, with FDA-agreed protocol changes reducing observation periods and enabling broader access. Nkarta aims to prove CAR NK therapy's efficacy and safety, targeting a potential registrational study by late 2027.
Advertisement

H.C. Wainwright Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $14

https://www.moomoo.com/news/post/1000019762/hc-wainwright-maintains-nkarta-nktxus-with-buy-rating-maintains-target
H.C. Wainwright has reiterated its Buy rating for Nkarta (NKTX.US) and maintained a target price of $14. This indicates continued confidence from the analyst firm in the company's prospects.

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

https://www.tradingview.com/news/marketbeat:c88ee5aef094b:0-nkarta-targets-acr-2026-data-reveal-as-outpatient-car-nk-trials-advance/
Nkarta (NKTX) plans to present initial clinical data from its autoimmune disease CAR NK cell therapy programs at the American College of Rheumatology’s 2026 Convergence meeting. The company has amended protocols to allow for outpatient administration of its allogeneic, off-the-shelf CD19-targeted CAR NK cell therapy, aiming for broader patient access and therapeutic benefits similar to CAR T therapies. Nkarta will present data on myositis, scleroderma, and program-wide safety, expecting to narrow its focus on specific indications for future registrational efforts.

Nkarta at stifel forum: safer cell therapy push gains traction By Investing.com

https://ca.investing.com/news/stock-market-news/nkarta-at-stifel-forum-safer-cell-therapy-push-gains-traction-93CH-4850534
Nkarta Therapeutics presented at the Stifel 2026 Virtual Immunology and Inflammation Forum, detailing its strategy for a CD19-targeted CAR natural killer cell therapy in autoimmune diseases. The company highlighted FDA-approved protocol changes that have improved patient enrollment and convenience, emphasizing its off-the-shelf approach as a safer alternative to CAR T therapies, particularly for chronic autoimmune conditions. Nkarta plans to narrow its development focus to a few key indications and expects to present significant autoimmune data at the ACR Convergence 2026 meeting in November, with registrational trials potentially starting before the end of 2027.

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology Convergence 2026

https://investingnews.com/nkarta-to-present-initial-autoimmune-clinical-data-for-nkx019-at-american-college-of-rheumatology-convergence-2026/
Nkarta, Inc. (Nasdaq: NKTX) announced that three scientific presentations, including two oral presentations and one poster presentation, focusing on its investigational CAR-NK cell therapy, NKX019, have been selected for ACR Convergence 2026. The presentations will highlight NKX019's safety profile across autoimmune indications, clinical activity in idiopathic inflammatory myopathy, and clinical activity in systemic sclerosis. Nkarta CEO Paul J. Hastings emphasized the potential of NKX019's tolerability, early efficacy, off-the-shelf availability, and outpatient dosing to significantly broaden patient access to cell therapy for devastating autoimmune conditions.

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

https://www.stocktitan.net/news/NKTX/nkarta-to-present-initial-autoimmune-clinical-data-for-nkx019-at-v6jesal8igcy.html
Nkarta (NKTX) will present initial autoimmune clinical data for its investigational CAR-NK therapy NKX019 at ACR Convergence 2026 in Orlando. The company will deliver two oral presentations and one poster, covering the safety and clinical activity of NKX019 in idiopathic inflammatory myopathy, systemic sclerosis, and B-cell-mediated autoimmune diseases. These presentations mark an important milestone for Nkarta as they share their first overview of NKX019's safety profile and clinical activity.
Advertisement

Nkarta to Participate in September Investor Conferences

https://investingnews.com/nkarta-to-participate-in-september-investor-conferences/
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company, announced its participation in two upcoming investor conferences in September 2026. The company will hold fireside chats at the H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. Webcasts of these events will be available on Nkarta's investor website.

Nkarta Insiders Got A Good Deal Selling At US$2.10

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktx/nkarta/news/nkarta-insiders-got-a-good-deal-selling-at-us210
Nkarta, Inc. insiders may have missed out on recent stock gains after selling shares earlier in the year at US$2.07, below the current price of US$3.23. The CEO and Director, Paul Hastings, sold a significant portion of his stake, and while there has been insider selling, the amounts are considered small. The article notes low insider ownership and suggests caution, while also pointing out four warning signs for the company.

Nkarta to Participate in September Investor Conferences

https://www.globenewswire.com/news-release/2026/09/10/3359350/0/en/nkarta-to-participate-in-september-investor-conferences.html
Nkarta, Inc. announced its participation in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. The clinical-stage biopharmaceutical company will hold fireside chats at both events, with webcasts available on its investor relations website. Nkarta is focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases.

Two Nkarta investor talks will be webcast in September

https://www.stocktitan.net/news/NKTX/nkarta-to-participate-in-september-investor-g0uc2f9p57v3.html
Nkarta (NKTX) announced its participation in two investor conferences in September 2026. The company will be featured in fireside chats at the H.C. Wainwright 28th Annual Global Investment Conference on September 16 and the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23. Webcasts and replays of these events will be accessible on Nkarta's investor relations website for approximately 90 days.

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

https://finance.yahoo.com/healthcare/articles/nkarta-present-initial-autoimmune-clinical-110000235.html
Nkarta, Inc. announced its selection for three scientific presentations at ACR Convergence 2026, where it will present initial autoimmune clinical data for NKX019. Two oral presentations will highlight the safety of NKX019 across all autoimmune indications and its clinical activity in idiopathic inflammatory myopathy, while a poster presentation will detail its clinical activity in systemic sclerosis. This marks an important milestone for Nkarta as it shares the first overview of NKX019's safety profile and early efficacy in autoimmune conditions.
Advertisement

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

https://www.globenewswire.com/news-release/2026/09/08/3357471/0/en/nkarta-to-present-initial-autoimmune-clinical-data-for-nkx019-at-american-college-of-rheumatology-acr-convergence-2026.html
Nkarta, Inc. announced its selection for three scientific presentations at ACR Convergence 2026, highlighting initial autoimmune clinical data for its investigational CAR-NK cell therapy, NKX019. The presentations will cover the overall safety profile and clinical activity of NKX019 in idiopathic inflammatory myopathy and systemic sclerosis. This represents a significant milestone for Nkarta, showcasing the potential of NKX019 for broad patient access due to its tolerability, early efficacy, off-the-shelf availability, and outpatient dosing capability.

Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

https://www.marketbeat.com/instant-alerts/filing-monaco-asset-management-sam-makes-new-investment-in-nkarta-inc-nktx-2026-08-17/
Monaco Asset Management SAM has acquired a new stake of 2.37 million shares in Nkarta, Inc. (NASDAQ:NKTX), valued at approximately $6.7 million, making it their 13th largest position and representing 3.32% of Nkarta. Despite Nkarta missing analyst expectations for its last quarterly earnings with a loss of $0.54 per share, institutional investors now own 80.54% of the company. Analyst sentiment remains a "Moderate Buy" with an average price target of $11.20, although some firms have lowered price objectives and earnings estimates due to projected continued losses.

Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen

https://www.marketbeat.com/instant-alerts/nkarta-nasdaqnktx-stock-rating-lowered-by-wall-street-zen-2026-08-15/
Wall Street Zen has downgraded Nkarta (NASDAQ:NKTX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an $11.20 target. Nkarta's shares opened at $2.33, near its 1-year low, and the company reported a quarterly loss of $0.54 per share, worse than estimates. Institutional investors hold a significant portion of the company's stock, and analysts project a full-year loss of $1.54 per share.

Stifel cuts Nkarta stock price target on updated model

https://www.investing.com/news/analyst-ratings/stifel-cuts-nkarta-stock-price-target-on-updated-model-93CH-4860838
Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) from $11.00 to $10.00, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated model. The adjustment reflects ongoing patient enrollment progress in Nkarta's Ntrust-1/2 trials and upcoming preliminary data expected by year-end 2026. Despite the target cut, InvestingPro data suggests the stock may be undervalued, noting Nkarta's strong cash position but also its rapid cash burn, a common characteristic for clinical-stage biotech firms.

Stifel cuts Nkarta stock price target on updated model By Investing.com

https://ca.investing.com/news/stock-market-news/stifel-cuts-nkarta-stock-price-target-on-updated-model-93CH-4801467
Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $10 from $11, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated financial model. The adjustment comes after discussions with Nkarta's management regarding patient enrollment progress in its Ntrust-1/2 trials and anticipated preliminary data by the end of 2026. Despite the price target cut, InvestingPro data suggests Nkarta may be undervalued, although the biotech company is noted for rapidly burning through cash, a common trait for firms in clinical development.
Advertisement

Stifel cuts Nkarta stock price target on updated model

https://m.investing.com/news/analyst-ratings/stifel-cuts-nkarta-stock-price-target-on-updated-model-93CH-4860838?ampMode=1
Stifel lowered its price target on Nkarta Inc. (NASDAQ:NKTX) to $10.00 from $11.00, maintaining a Buy rating, following the company's Q2 2026 earnings and an updated model. The firm discussed patient enrollment progress in the Ntrust-1/2 trials and anticipates preliminary data by the end of 2026. Despite a strong balance sheet, Nkarta is rapidly burning cash, a common issue for biotechs in clinical development.

Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price

https://www.marketbeat.com/instant-alerts/stifel-nicolaus-has-lowered-expectations-for-nkarta-nasdaqnktx-stock-price-2026-08-14/
Stifel Nicolaus has reduced its price target for Nkarta (NASDAQ:NKTX) from $11 to $10, while maintaining a "buy" rating, indicating a potential upside of 334.78% from the previous close. The company's shares opened at $2.30 and were down 3.8% after reporting a quarterly loss of $0.54 per share, missing analyst expectations. Despite mixed analyst sentiment, the consensus remains a "Moderate Buy" with an average target price of $11.20, and institutional investors hold a significant 80.54% stake in the company.

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

https://www.globenewswire.com/news-release/2026/08/10/3342262/0/en/nkarta-reports-second-quarter-2026-financial-results-and-corporate-highlights.html
Nkarta, Inc. reported its second-quarter 2026 financial results, highlighting continued patient enrollment in its Ntrust-1 and Ntrust-2 clinical trials for NKX019 in autoimmune diseases, with initial data expected in 2026. The company's cash balance of $243.2 million as of June 30, 2026, is projected to fund operations into 2029. Nkarta emphasized expanding outpatient dosing through community-based sites, improving patient access to the NKX019 therapy.

Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside

https://www.tradingview.com/news/tradingview:2e7bb05865c2d:0-nkarta-inc-stock-12-month-price-target-cut-to-11-implies-347-upside/
Nkarta, Inc. (NKTX) has seen its average 12-month price target cut to $11 from $11.33 by analysts, with forecasts ranging from $9 to $14 per share. This updated target suggests a potential upside of approximately 347% based on the recent closing price. The consensus rating for the stock remains a "Buy" among the 8 covering analysts.

H.C. Wainwright cuts Nkarta stock price target on trial progress

https://m.investing.com/news/analyst-ratings/hc-wainwright-cuts-nkarta-stock-price-target-on-trial-progress-93CH-4851381?ampMode=1
H.C. Wainwright lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $14 from $16, while maintaining a Buy rating. The firm's decision followed Nkarta's Q2 2026 earnings report and an update on its Ntrust-1 and Ntrust-2 trials for NKX019 in autoimmune diseases, with initial data expected in late 2026. Despite strong liquidity, InvestingPro Tips indicate the company is rapidly burning cash.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement